IMI RAPID-COVID PROJECT

During this 15-month project, the consortium aims to analytically and clinically validate (CE mark) a test that can simultaneously detect and differentiate SARS-CoV-2 as well as 16 other common respiratory diseases (bacteria and viruses).
Everything will be automated on our ACSIA platform.

Ultimately, this technology will provide maximum flexibility in screening and triage, enabling better and faster care, relieving pressure on healthcare systems and improving patient recovery rates.

This project received funding from the Innovative Medicines Initiative Joint Undertaking (JU) 2 under Grant Agreement No 101005144. The Joint Undertaking receives support from the research program and Horizon 2020 innovation from the European Union and EFPIA.

PROJET FEDER POUR LE TYPAGE HLA PAR SÉQUENÇAGE NGS

The NGS2HLA project aims to "Develop an innovative and comprehensive HLA typing solution for kidney transplantation and Immunology". It is supported by the Assistance Publique des Hôpitaux de Paris (APHP) as well as two innovative companies (PrimaDiag and Wiratech). It was labeled by the Medicen Paris Region competitiveness cluster on October 29, 2015 and passed into committee at the Ile de France Regional Council. As such, it benefits from ERDF funding.

The project consists of developing a complete HLA typing offer by NGS sequencing, which will consist at the end of the program of a diagnostic automaton, associated biological reagents and bioinformatics analysis software.

Each member of the consortium masters the expertise necessary for this ambitious project:

1. PrimaDiag for the development part of the controller and validation of automated protocols
2. Wiratech for product design (kit) and development of bioinformatics analysis tools (software).
3. APHP for preparing RNA banks, optimizing amplification PCR and performing NGS sequencing on the Institut Universitaire d'Hematology platform at Saint-Louis Hospital.